Logo image of SCYX

SCYNEXIS INC (SCYX) Stock Fundamental Analysis

NASDAQ:SCYX - US8112922005 - Common Stock

0.816 USD
+0 (+0.21%)
Last: 8/22/2025, 8:00:02 PM
Fundamental Rating

4

Overall SCYX gets a fundamental rating of 4 out of 10. We evaluated SCYX against 193 industry peers in the Pharmaceuticals industry. While SCYX seems to be doing ok healthwise, there are quite some concerns on its profitability. SCYX has a decent growth rate and is not valued too expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

SCYX had negative earnings in the past year.
SCYX had a negative operating cash flow in the past year.
SCYX had negative earnings in 4 of the past 5 years.
SCYX had negative operating cash flow in 4 of the past 5 years.
SCYX Yearly Net Income VS EBIT VS OCF VS FCFSCYX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M

1.2 Ratios

SCYX has a Return On Assets (-32.16%) which is in line with its industry peers.
SCYX's Return On Equity of -43.89% is in line compared to the rest of the industry. SCYX outperforms 56.48% of its industry peers.
Industry RankSector Rank
ROA -32.16%
ROE -43.89%
ROIC N/A
ROA(3y)-14.27%
ROA(5y)-24.82%
ROE(3y)-636.53%
ROE(5y)-446.25%
ROIC(3y)N/A
ROIC(5y)N/A
SCYX Yearly ROA, ROE, ROICSCYX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K

1.3 Margins

SCYX has a better Gross Margin (114.98%) than 100.00% of its industry peers.
In the last couple of years the Gross Margin of SCYX has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for SCYX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 114.98%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.8%
GM growth 5YN/A
SCYX Yearly Profit, Operating, Gross MarginsSCYX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K -40K

More info and screens

6

2. Health

2.1 Basic Checks

SCYX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SCYX has more shares outstanding
SCYX has more shares outstanding than it did 5 years ago.
The debt/assets ratio for SCYX is higher compared to a year ago.
SCYX Yearly Shares OutstandingSCYX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
SCYX Yearly Total Debt VS Total AssetsSCYX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

SCYX has an Altman-Z score of -8.74. This is a bad value and indicates that SCYX is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of SCYX (-8.74) is worse than 65.80% of its industry peers.
SCYX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -8.74
ROIC/WACCN/A
WACC9.9%
SCYX Yearly LT Debt VS Equity VS FCFSCYX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M

2.3 Liquidity

A Current Ratio of 5.20 indicates that SCYX has no problem at all paying its short term obligations.
SCYX has a Current ratio of 5.20. This is in the better half of the industry: SCYX outperforms 71.50% of its industry peers.
SCYX has a Quick Ratio of 5.20. This indicates that SCYX is financially healthy and has no problem in meeting its short term obligations.
With a decent Quick ratio value of 5.20, SCYX is doing good in the industry, outperforming 73.06% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.2
Quick Ratio 5.2
SCYX Yearly Current Assets VS Current LiabilitesSCYX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 44.44% over the past year.
SCYX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -66.43%.
Measured over the past years, SCYX shows a very strong growth in Revenue. The Revenue has been growing by 99.01% on average per year.
EPS 1Y (TTM)44.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%53.33%
Revenue 1Y (TTM)-66.43%
Revenue growth 3Y-34.22%
Revenue growth 5Y99.01%
Sales Q2Q%85.33%

3.2 Future

SCYX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 24.09% yearly.
SCYX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 36.50% yearly.
EPS Next Y38.57%
EPS Next 2Y82.67%
EPS Next 3Y68.75%
EPS Next 5Y24.09%
Revenue Next Year48.11%
Revenue Next 2Y124.59%
Revenue Next 3Y108.87%
Revenue Next 5Y36.5%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
SCYX Yearly Revenue VS EstimatesSCYX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M
SCYX Yearly EPS VS EstimatesSCYX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -10 -20 -30 -40 -50

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

SCYX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
With a Price/Forward Earnings ratio of 1.39, the valuation of SCYX can be described as very cheap.
Based on the Price/Forward Earnings ratio, SCYX is valued cheaply inside the industry as 99.48% of the companies are valued more expensively.
Compared to an average S&P500 Price/Forward Earnings ratio of 35.82, SCYX is valued rather cheaply.
Industry RankSector Rank
PE N/A
Fwd PE 1.39
SCYX Price Earnings VS Forward Price EarningsSCYX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SCYX Per share dataSCYX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
SCYX's earnings are expected to grow with 68.75% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y82.67%
EPS Next 3Y68.75%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SCYX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SCYNEXIS INC

NASDAQ:SCYX (8/22/2025, 8:00:02 PM)

0.816

+0 (+0.21%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-13 2025-08-13/amc
Earnings (Next)11-04 2025-11-04/amc
Inst Owners29.92%
Inst Owner Change-5.88%
Ins Owners2.24%
Ins Owner Change3.93%
Market Cap34.21M
Analysts84.44
Price Target4.76 (483.33%)
Short Float %1.27%
Short Ratio2.93
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)33.07%
Min EPS beat(2)27.76%
Max EPS beat(2)38.38%
EPS beat(4)4
Avg EPS beat(4)36.63%
Min EPS beat(4)20.51%
Max EPS beat(4)59.89%
EPS beat(8)6
Avg EPS beat(8)23.48%
EPS beat(12)8
Avg EPS beat(12)7.4%
EPS beat(16)11
Avg EPS beat(16)17.41%
Revenue beat(2)2
Avg Revenue beat(2)395.48%
Min Revenue beat(2)22.61%
Max Revenue beat(2)768.35%
Revenue beat(4)2
Avg Revenue beat(4)152.71%
Min Revenue beat(4)-90.6%
Max Revenue beat(4)768.35%
Revenue beat(8)5
Avg Revenue beat(8)170.56%
Revenue beat(12)8
Avg Revenue beat(12)116.76%
Revenue beat(16)9
Avg Revenue beat(16)82.59%
PT rev (1m)0%
PT rev (3m)-6.67%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-15.15%
EPS NY rev (1m)0%
EPS NY rev (3m)15.87%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-96.89%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-8.91%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 1.39
P/S 10.5
P/FCF N/A
P/OCF N/A
P/B 0.77
P/tB 0.77
EV/EBITDA N/A
EPS(TTM)-0.4
EYN/A
EPS(NY)0.59
Fwd EY72.08%
FCF(TTM)-0.57
FCFYN/A
OCF(TTM)-0.57
OCFYN/A
SpS0.08
BVpS1.06
TBVpS1.06
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -32.16%
ROE -43.89%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 114.98%
FCFM N/A
ROA(3y)-14.27%
ROA(5y)-24.82%
ROE(3y)-636.53%
ROE(5y)-446.25%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.8%
GM growth 5YN/A
F-Score4
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.2
Quick Ratio 5.2
Altman-Z -8.74
F-Score4
WACC9.9%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)44.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%53.33%
EPS Next Y38.57%
EPS Next 2Y82.67%
EPS Next 3Y68.75%
EPS Next 5Y24.09%
Revenue 1Y (TTM)-66.43%
Revenue growth 3Y-34.22%
Revenue growth 5Y99.01%
Sales Q2Q%85.33%
Revenue Next Year48.11%
Revenue Next 2Y124.59%
Revenue Next 3Y108.87%
Revenue Next 5Y36.5%
EBIT growth 1Y29.6%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-336.99%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-336.99%
OCF growth 3YN/A
OCF growth 5YN/A